Fig. 3
Pooled estimates of overall survival and progression-free survival. BSC, Best Supportive Care; REDo, regorafenib dose optimization; TAS-102, trifluridine/tipiracil; TAS-BEV, TAS-102 with bevacizumab
Fig. 3 | Health Economics Review